Allen C.a· Gautam S.b· Cheng W.c· Pine A.B.a· Podoltsev N.A.a· Zeidan A.M.a· Lee A.I.a· Shallis R.M.a

Author affiliations

aSection of Hematology, Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT, USA
bSection of Pulmonary, Critical Care and Sleep Medicine, Department of Internal Medicine, Yale School of Medicine, Yale University, New Haven, CT, USA
cDepartment of Biostatistics, Yale School of Public Health, Yale University, New Haven, CT, USA

Log in to MyKarger to check if you already have access to this content.

Buy FullText & PDF Unlimited re-access via MyKarger Unrestricted printing, no saving restrictions for personal use read more

CHF 38.00 *
EUR 35.00 *
USD 39.00 *

Select

KAB

Buy a Karger Article Bundle (KAB) and profit from a discount!

If you would like to redeem your KAB credit, please log in.

Save over 20% compared to the individual article price.

Learn more

Rent via DeepDyve Unlimited fulltext viewing of this article Organize, annotate and mark up articles Printing and downloading restrictions apply

Start free trial

Subscribe Access to all articles of the subscribed year(s) guaranteed for 5 years Unlimited re-access via Subscriber Login or MyKarger Unrestricted printing, no saving restrictions for personal use read more

Subcription rates

Select

* The final prices may differ from the prices shown due to specifics of VAT rules.

Article / Publication Details

Received: January 10, 2023
Accepted: March 09, 2023
Published online: April 26, 2023

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 2

ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)

For additional information: https://www.karger.com/AHA

Abstract

Patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) often receive antibacterial prophylaxis. Antibacterial agents can cause elevations in the prothrombin time and international normalized ratio (INR). The impact of prophylactic antibacterials on the coagulation profiles and bleeding risk in patients with AML/MDS is unknown. We evaluated patients with AML or MDS who were being admitted to the hospital. The cohort was divided into two groups of patients: (1) those receiving and (2) those not receiving prophylactic antibacterials, at the time of admission. We conducted a retrospective cohort study of adult patients with AML/MDS admitted to Yale-New Haven Hospital between 2015–2019. The study was approved by the Yale Institutional Review Board. Inclusion criteria included patients >18 years old with a diagnosis of AML or MDS admitted to the hospital. We identified 150 individual patient encounters with active AML/MDS admitted to Yale-New Haven of which 32 occurred while on and 118 while off antibacterial prophylaxis. Median duration of pre-admission antibacterial exposure was 2 (range: 0.07–24) months. Patients on antibacterial prophylaxis had higher INR (median 1.14 vs. 1.03, p = 0.0002), and higher partial thromboplastin time prolongation (median 26.5 vs. 24.3, p < 0.0014), than patients without antibacterial prophylaxis. Patients without antibacterial prophylaxis had higher rates of bleeding using the ISTH-defined criteria (24.6% vs. 6.3%, p = 0.043), including higher rates of ISTH major (2 vs. 0) and clinically relevant bleeding (9 vs. 0). Patients with AML/MDS on antibacterial prophylaxis were more likely to have an abnormal coagulation profile when compared with their counterparts not on prophylaxis. Conversely, rates of bleeding were higher in patients not on prophylaxis. These data suggest that prophylactic antibacterials do not increase bleeding risk in patients with AML/MDS.

© 2023 S. Karger AG, Basel

References Taplitz RA, Kennedy EB, Flowers CR. Antimicrobial prophylaxis for adult patients with cancer-related immunosuppression: ASCO and IDSA clinical practice guideline update summary. J Oncol Pract. 2018 Nov;14(11):692–5. NCCN clinical practice guidelines in Oncology2022. NCCN guidelines (version 1.2022) prevention and treatment of cancer-related infections. Babiak LM, Rybak MJ. Hematological effects associated with beta-lactam use. Drug Intell Clin Pharm. 1986 Nov;20(11):833–6. Sieradzan RR, Bottner WA, Fasco MJ, Bertino JSJr. Comparative effects of cefoxitin and cefotetan on vitamin K metabolism. Antimicrob Agents Chemother. 1988 Sep;32(9):1446–9. Jolson HM, Tanner LA, Green L, Grasela THJr. Adverse reaction reporting of interaction between warfarin and fluoroquinolones. Arch Intern Med. 1991;151(5):1003–4. Park GH, Kim S, Kim MS, Yu YM, Kim GH, Lee JS, et al. The association between cephalosporin and hypoprothrombinemia: a systematic review and meta-analysis. Int J Environ Res Public Health. 2019 Oct 16;16(20):3937. Williams KJ, Bax RP, Brown H, Machin SJ. Antibiotic treatment and associated prolonged prothrombin time. J Clin Pathol. 1991 Sep;44(9):738–41. Fainstein V, Bodey GP, McCredie KB, Keating MJ, Estey EH, Bolivar R, et al. Coagulation abnormalities induced by beta-lactam antibiotics in cancer patients. J Infect Dis. 1983 Oct;148(4):745–50. Alperin JB. Coagulopathy caused by vitamin K deficiency in critically ill, hospitalized patients. J Am Med Assoc. 1987 Oct 9;258(14):1916–9. Dixit A, Chatterjee T, Mishra P, Kannan M, Choudhry DR, Mahapatra M, et al. Disseminated intravascular coagulation in acute leukemia at presentation and during induction therapy. Clin Appl Thromb Hemost. 2007 Jul;13(3):292–8. Libourel EJ, Klerk CPW, van Norden Y, de Maat MPM, Kruip MJ, Sonneveld P, et al. Disseminated intravascular coagulation at diagnosis is a strong predictor for thrombosis in acute myeloid leukemia. Blood. 2016 Oct 6;128(14):1854–61. Taylor FBJr, Toh CH, Hoots K, Wada H, Levi M; Scientific Subcommittee on Disseminated Intravascular Coagulation DIC of the International Society on Thrombosis and Haemostasis ISTH. Towards definition, clinical and laboratory criteria, and a scoring system for disseminated intravascular coagulation. Thromb Haemost. 2001 Nov;86(11):1327–30. Suzuki K, Wada H, Imai H, Iba T, Thachil J, Toh CH, et al. A re-evaluation of the D-dimer cut-off value for making a diagnosis according to the ISTH overt-DIC diagnostic criteria: communication from the SSC of the ISTH. J Thromb Haemost. 2018 Jul;16(7):1442–4. Schulman S, Kearon C; Subcommittee on Control of Anticoagulation of the Scientific and Standardization Committee of the International Society on Thrombosis and Haemostasis. Definition of major bleeding in clinical investigations of antihemostatic medicinal products in non-surgical patients. J Thromb Haemost. 2005 Apr;3(4):692–4. Kaatz S, Ahmad D, Spyropoulos AC, Schulman S; Subcommittee on Control of Anticoagulation. Definition of clinically relevant non-major bleeding in studies of anticoagulants in atrial fibrillation and venous thromboembolic disease in non-surgical patients: communication from the SSC of the ISTH. J Thromb Haemost. 2015 Nov;13(11):2119–26. Custer GM, Briggs BR, Smith RE. Effect of cefamandole nafate on blood coagulation and platelet function. Antimicrob Agents Chemother. 1979 Dec;16(6):869–72. Cohen H, Mackie IJ, Walshe K, Shearer M, Bax R, Pozniak A, et al. The effects of cefotetan disodium on haemostasis. J Hosp Infect. 1987 Jul;10(1):51–7. Shimada K, Matsuda T, Inamatsu T, Urayama K. Bleeding secondary to vitamin K deficiency in patients receiving parenteral cephem antibiotics. J Antimicrob Chemother. 1984;14(Suppl B):325–30. Article / Publication Details

Received: January 10, 2023
Accepted: March 09, 2023
Published online: April 26, 2023

Number of Print Pages: 6
Number of Figures: 0
Number of Tables: 2

ISSN: 0001-5792 (Print)
eISSN: 1421-9662 (Online)

For additional information: https://www.karger.com/AHA

Copyright / Drug Dosage / Disclaimer Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.